It is a broadly described annual report of The IBN SINA Pharmaceutical Industry Limited in the year of 2011. During the financial year, Company’s EPS stood at Tk. 5.46 which was Tk. 4.64 in 2010. In the year under review Net Asset Value per share was Tk.25.37 which was Tk. 20.74 in 2010. Total Net Asset Value (NAV) in 2011 was Tk.32, 87, 43,186.00 while in the previous year it was Tk. 26, 87, 31,129.00. Net Operating Cash Flow per Share (NOCFPS) was Tk. 7.50 as against Tk. 10.93 in the previous year. In 2011, the total sales of the Company reached to 11.1755 26 million which was 9.35% higher than that of 2010. The earnings per share rose to Tk.5.46. The net profit increased by 7.75% than the last year. The external liability per one Taka shareholders equity reduced to 11.0.24.
The Company’s reserves and surplus rose to Tk.199,143,186.00 which was 11.160, 731,129.00 in the previous year. After evaluating the Financial Statements of the Company in the year 2011, the Board of Directors proposed a stock dividend of 25% and the cash dividend of 10% per share of Tk.10 each.
More Annual Report of The IBN SINA Pharmaceutical Industry Limited:
- Annual Report 2010 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2011 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2012 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2013 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2014 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2017 of The IBN SINA Pharmaceutical Industry Limited
